1. AydoĞan TÜrkoĞlu, Sümeyye, Dayi, Gizem, KÖÇkar, Feray. 2020. Upregulation of PSMD4 gene by hypoxia in prostate cancer cells. In Turkish journal of biology = Turk biyoloji dergisi, 44, 275-283. doi:10.3906/biy-2002-71. https://pubmed.ncbi.nlm.nih.gov/33110365/
2. Zhang, Jiamin, Fang, Shu, Rong, Fanghao, Cui, Huixian, Hao, Peipei. 2023. PSMD4 drives progression of hepatocellular carcinoma via Akt/COX2 pathway and p53 inhibition. In Human cell, 36, 1755-1772. doi:10.1007/s13577-023-00935-1. https://pubmed.ncbi.nlm.nih.gov/37336868/
3. Ma, Ai-Guo, Yu, Li-Mei, Zhao, Hong, Tian, Xiang-Yu, Wang, Qing. 2019. PSMD4 regulates the malignancy of esophageal cancer cells by suppressing endoplasmic reticulum stress. In The Kaohsiung journal of medical sciences, 35, 591-597. doi:10.1002/kjm2.12093. https://pubmed.ncbi.nlm.nih.gov/31162820/
4. Liapis, Konstantinos, Kastritis, Efstathios, Bagratouni, Tina, Delimpasi, Sosanna, Dimopoulos, Meletios A. . Early tumor-cell gene expression changes may predict the response to first-line bortezomib-based therapy in patients with newly diagnosed multiple myeloma. In Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 20, 1314-21. doi:. https://pubmed.ncbi.nlm.nih.gov/26537080/
5. Li, Ying, Zhou, Qin, Shen, Jing, Zhu, Lixia. . Down-regulation of PSMD4 can attenuate autophagy, enhance the accumulation of intracellular ROS, and increase the sensitivity of epithelial ovarian cancer to carboplatin by inhibiting the NF-κB pathway. In Translational cancer research, 10, 4756-4772. doi:10.21037/tcr-21-1389. https://pubmed.ncbi.nlm.nih.gov/35116329/
6. Garcia, Jessica Burroughs, Storti, Paola, Iannozzi, Nicolas Thomas, Donofrio, Gaetano, Giuliani, Nicola. 2024. Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma. In Haematologica, 109, 627-631. doi:10.3324/haematol.2023.283200. https://pubmed.ncbi.nlm.nih.gov/37608776/
智鼠故事 
